Provenge – Sipuleucel-T may have added benefit in prostate cancer

Sipuleucel-T in prostate cancer: Indication of added benefit – Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T.

Mammography screening for breast cancer needs individualized approach

The mammography dilemma — Complex benefits and harms of mammography require individualized approach – A comprehensive review of 50 year’s worth of international studies assessing the benefits and harms of mammography screening suggests that the benefits of the screening are often overestimated, while harms are underestimated.

Blood stem cells longevity mechanism discovered

Mechanism Behind Blood Stem Cells’ Longevity Discovered – The blood stem cells that live in bone marrow are at the top of a complex family tree. Such stem cells split and divide down various pathways that ultimately produce red cells, white cells and platelets. These “daughter” cells must be produced at a rate of about one million per second to constantly replenish the body’s blood supply.

Prostate cancer – A change in circulating tumor cells detection has high potential in the prediction

Prostate cancer: A change in circulating tumor cells detection has high potential in the prediction – A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen levels.

Pazopanib better than sunitinib in advanced kidney cancer

Pazopanib shows better quality-of-life in advanced kidney cancer – Two oral targeted drugs — Pazopanib (Votrient) and sunitinib (Sutent) — approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, the safety profile and many measures of quality of life favored pazopanib.

Kadcyla – new treatment for late stage HER2 breast cancer

US FDA approves new treatment for late-stage breast cancer – Kadcyla (ado-trastuzumab emtansine) – a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer is approved by US FDA. Breast cancer is the second leading cause of cancer-related death among women. Almost 20 percent of breast cancers have increased amounts of the HER2 protein.

Do NOT follow this link or you will be banned from the site!